Pyrimidinones

"Pyrimidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.

Descriptor ID	D011744
MeSH Number(s)	D03.383.742.698
Concept/Terms	Pyrimidinones Pyrimidinones Pyrimidones Pyrimidones

Below are MeSH descriptors whose meaning is more general than "Pyrimidinones".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidinones [D03.383.742.698]

Below are MeSH descriptors whose meaning is related to "Pyrimidinones".

Below are MeSH descriptors whose meaning is more specific than "Pyrimidinones".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrimidinones" by people in this website by year, and whether "Pyrimidinones" was a major or minor topic of these publications.

Bar chart showing 11 publications over 8 distinct years, with a maximum of 2 publications in 2007 and 2009 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2007	1	1	2
2008	0	1	1
2009	0	2	2
2019	1	0	1
2020	0	1	1
2023	0	1	1
2025	1	1	2

Below are the most recent publications written about "Pyrimidinones" by people in Profiles.

Barajas J, Yang Z, Agyare E, Zhu X, Yoon SJ, Han B. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. PLoS One. 2025; 20(12):e0326550.

View in: PubMed
Yang C, Pang X, Teng S, Wilson S, Gu X, Xie G. MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2025 Jan 12; 26(2).

View in: PubMed
Rodr?guez-V?zquez GO, Diaz-Qui?ones AO, Chorna N, Salgado-Villanueva IK, Tang J, Ortiz WIS, Maldonado HM. Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints. Biomed Pharmacother. 2023 Oct; 166:115352.

View in: PubMed
Ahmad S, He Q, Williams KP, Scott JE. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach. SLAS Discov. 2020 09; 25(8):923-938.

View in: PubMed
Young LA, O'Connor LO, de Renty C, Veldman-Jones MH, Dorval T, Wilson Z, Jones DR, Lawson D, Odedra R, Maya-Mendoza A, Reimer C, Bartek J, Lau A, O'Connor MJ. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Res. 2019 07 15; 79(14):3762-3775.

View in: PubMed
Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009 Jul 13; 169(13):1224-32.

View in: PubMed
Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 2009 Jun; 63(6):1244-50.

View in: PubMed
Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dub? MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76.

View in: PubMed
Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):193-200.

View in: PubMed
Brown JD, Kangwanprasert M, Tice A, Melish J. Thyrotoxic periodic paralysis in a Polynesian male following highly active antiretroviral therapy for HIV infection. Hawaii Med J. 2007 Mar; 66(3):60, 62-3.

View in: PubMed

People

Explore

Similar Concepts

Top Journals